

REMARKS

The present invention relates to certain cyclopentane heptanoic acid, 2-arylalkyl compounds, which comprise an omega chain chlorophenoxy or trifluoromethylphenoxy and are useful in treating glaucoma and ocular hypertension and pharmaceutical compositions useful in such treatment.

The applicants have filed claims 26 through 45 to specifically copy claims 1 through 20 of U.S. Patent No. 5,510,383 ("Bishop") and request that the Examiner declare an interference to determine the priority of invention as to the subject matter of these added claims. The claims copied from Bishop are supported in the present specification as follows:

Bishop, Claim 1
Woodward Claim 26

Support in
Present Application

R¹ is hydrogen

Claim 1, X is OR⁴ and R⁴ may be hydrogen

R¹ is C₁-C₁₂ alkyl, etc.

Claim 1, R⁴ may be lower alkyl

R¹ is a pharmaceutically acceptable amine

Claim 1, compound of formula I, includes pharmaceutically-acceptable salts

R¹ is a cationic salt

Claim 1, compound of formula I, includes pharmaceutically-acceptable salts

R² is Cl or CF₃

Claim 4, Y¹ is Cl or trifluoromethyl

Bishop Claim 2
Woodward Claim 27

Claim 1 R⁴ may be hydrogen or lower alkyl. See also, page 10, lines 25 and 26 wherein lower alkyl includes methyl, propyl and butyl

R¹ is H, CH₃, CH(CH₃)₂

RECEIVED TELETYPE UNIT

R^1 is H, CH_3 , $CH(CH_3)_2$
and $C(CH_3)_3$

methyl, propyl and butyl

Bishop Claim 3
Woodward Claim 28

Claim 1 includes pharmaceutically-acceptable salts. See also, page 13, line 5 wherein salt includes alkali metal salts

$$\text{R}^1 \text{ is } \text{Na}^+ \text{ or } \text{CH}_3\text{N}^+(\text{CH}_2\text{OH})_3.$$

Bishop Claim 4
Woodward Claim 29

R^2 is Cl

See claim 4 wherein Y¹ is Cl

Bishop Claim 5
Woodward Claim 30

$$R^2 \text{ is } CF^3$$

See claim 4 wherein Y¹ is trifluoromethyl

Bishop Claims 6-8
Woodward's Claims 31-33

between about 0.001
and about 1000
µg/eye of compound
is administered

See page 13, lines 12-14
 "therapeutically efficient amount
 is between about 0.0001 and 5% (w/v),
 preferably about 0.001 to about 1.0%
 w/v"

Bishop Claims 9-16
Woodward's Claims 34-41

Cover ophthalmic compositions useful in the method of claims 1-9 of Bishop and claims 26-33 of Woodward, respectively. The limitations of these claims mirror the limitations of the previously discussed method claims

Docket No. 16955DIVCONCIPCON(AP)

Bishop Claim 17
Woodward Claim 42

R¹ is a pharmaceutically
 acceptable ester moiety

See Claim 1, wherein Z is =O and
 X is -OR⁴, wherein R⁴ is a lower
 alkyl

R² is Cl or CF₃

See Claim 4 wherein Y¹ is Cl or
 trifluoromethyl

Bishop Claims 18-20
Woodward's Claims 43-45

(See discussion above.)

Respectfully Submitted,

RJ Baran

Robert J. Baran
 Registration No. 25,806
 Telephone: 714/246-4669
 Telecopier: 714/246-4249

ROBERT J. BARAN
 Legal Department (T2-2E)
 Allergan, Inc.
 2525 Dupont Drive
 Irvine, CA 92612-1599

Express Mail Number: EM272469880US Date of Deposit June 16, 1997
 I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED
 STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER
 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER OF
 PATENTS AND TRADEMARKS, WASHINGTON, D.C. 20231 on 6/16/97 (Date)

Bonnie Ferguson
 Bonnie Ferguson

6/16/97
 Date

0637637, 061697